Related Experiment Videos
Chronic allograft dysfunction: mechanisms and new approaches to therapy
K L Womer1, J P Vella, M H Sayegh
1Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Abstract:
Renal allograft failure is the most common cause of end-stage renal disease beyond the early posttransplantation period, accounting for 25% to 30% of patients awaiting renal transplantation. Despite recent advances in immunosuppressive therapy, improvements in long-term graft survival have not been commensurate with those observed in 1-year graft survival. The most common cause of chronic allograft loss is an incompletely understood clinicopathological entity sometimes called chronic rejection, chronic allograft dysfunction or in the case of kidneys, chronic allograft nephropathy. Although the precise mechanism(s) responsible for the characteristic pathological changes are still unclear, it is generally agreed that both alloantigen-dependent and alloantigen-independent factors influence the development of chronic allograft nephropathy. This article will address the potential mechanisms responsible for the pathogenesis of chronic dysfunction in solid organ grafts and the current approaches to management, including newer therapies designed to prevent the progression of the disease.
Insights
Chronic allograft nephropathy is a leading cause of kidney transplant failure, often driven by unclear mechanisms. This review explores its pathogenesis and management strategies to improve long-term graft survival.
Area of Science:
- Nephrology
- Transplantation Immunology
- Pathology
Background:
- Renal allograft failure is a major cause of end-stage renal disease, impacting 25-30% of transplant candidates.
- Long-term graft survival improvements lag behind early outcomes despite advances in immunosuppression.
- Chronic allograft nephropathy (CAN) is the primary driver of late graft loss, with incompletely understood mechanisms.
Purpose of the Study:
- To review the potential mechanisms underlying the pathogenesis of chronic dysfunction in solid organ grafts.
- To discuss current management approaches for chronic allograft nephropathy.
- To highlight newer therapies aimed at preventing disease progression.
Main Methods:
- Literature review of studies on chronic allograft nephropathy.
- Analysis of alloantigen-dependent and -independent factors in CAN development.
- Synthesis of current and emerging treatment strategies.
Main Results:
- Chronic allograft nephropathy involves complex interactions of immune and non-immune factors.
- Current management focuses on optimizing immunosuppression and addressing risk factors.
- Novel therapeutic targets are being investigated to prevent disease progression.
Conclusions:
- Understanding the multifaceted pathogenesis of CAN is crucial for improving long-term renal allograft survival.
- Integrated management strategies are needed to combat chronic allograft dysfunction.
- Further research into novel therapies holds promise for mitigating CAN and enhancing graft longevity.